Dong-A ST announced on Tuesday that its affiliate Meta via will present the latest clinical abstract (LBA) for DA-1726, a GLP-1 and glucagon dual-action obesity treatment, at the European Association for the Study of the Liver (EASL) annual congress, EASL Congress 2026.
The EASL Congress is a prestigious academic event where experts worldwide share cutting-edge guidelines and clinical data on major liver diseases, including MASH, liver cancer, and cirrhosis. This year’s EASL Congress 2026 is scheduled to take place from May 27 to May 30 in Barcelona, Spain.
During the poster presentation, Meta via’s Chief Medical Officer (CMO) Chris Pang will showcase research findings on DA-1726’s high-dose Phase 1 clinical trial. The presentation will cover safety, tolerability, pharmacokinetics, pharmacodynamics, and non-invasive liver assessment exploration.
DA-1726 is a novel drug candidate in the oxytomodulin analog class being developed to treat obesity. It targets both GLP-1 and glucagon receptors simultaneously, suppressing appetite, stimulating insulin secretion, and boosting basal metabolic rate in peripheral tissues. These combined effects aim to promote weight loss and improve blood sugar control.
Oxytomodulin, a hormone naturally produced in the human body, plays a crucial role in appetite suppression and increased energy expenditure. Oxytomodulin analogs are designed to mimic this hormone’s action.
Meta via is currently conducting Part 3 of the Phase 1 clinical trial, implementing one-step and two-step dose escalation strategies. These approaches aim to verify safety at high doses and optimize tolerability. The company expects to secure data by the fourth quarter of this year.
Meta via’s Chief Executive Officer (CEO), Kim Hyung-heon, expressed enthusiasm about the acceptance of DA-1726’s research results as the latest clinical abstract at the EASL annual congress. He stated that this is a significant milestone that validates the competitiveness and potential. DA-1726 is being developed as a next-generation obesity treatment with distinct competitive advantages.
